Is fluocinonide 0.05% a high‑potency topical corticosteroid?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Is Fluocinonide 0.05% High Potency?

Yes, fluocinonide 0.05% is classified as a high-potency (Class III) topical corticosteroid according to the European classification system. 1

Classification Details

According to the most recent 2026 guideline from Endocrine, fluocinonide 0.05% does not appear in the European classification tables provided, but the classification system clearly delineates:

  • Class I = Low potency (e.g., hydrocortisone 1%)
  • Class II = Medium potency (e.g., clobetasone butyrate 0.05%)
  • Class III = High potency (e.g., betamethasone valerate 0.1%, fluocinolone acetonide 0.025%, fluticasone propionate 0.05%, mometasone furoate 0.1%)
  • Class IV = Very high potency (e.g., clobetasol propionate 0.05%, halcinonide 0.01%) 1

Important Distinction

Fluocinonide 0.05% is high potency (Class III), NOT very high potency (Class IV). This is a critical distinction because:

  • Research directly comparing fluocinonide 0.05% to clobetasol propionate 0.05% (a Class IV very high potency steroid) demonstrates that clobetasol is significantly more potent than fluocinonide 2
  • Vasoconstriction assays confirm fluocinonide is less potent than clobetasol propionate 3
  • Fluocinonide 0.05% produces substantially less skin atrophy than clobetasol propionate formulations 4

Clinical Implications

Appropriate Use

Per the 2026 guideline, high-potency steroids like fluocinonide 0.05% are indicated for:

  • Chronic inflammatory lesions on trunk and extremities 1
  • NOT recommended for: face, eyelids, neck, genital areas, or thin-skinned regions (these require Class I-II agents)

Safety Profile

  • Fluocinonide 0.05% demonstrated superior efficacy to hydrocortisone 1% (27% vs 10% clearing/excellent improvement) 5
  • Lower atrophogenic potential compared to very high potency steroids 4
  • Can be used for longer courses than Class IV agents due to more favorable adverse effect profile 6

Common Pitfall

Do not confuse fluocinonide 0.05% with fluocinonide 0.1% cream (which exists but is less commonly used) or with halcinonide 0.01% (which is Class IV very high potency). The concentration and specific agent matter significantly for potency classification.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.